One of the most difficult cancers that is lung cancer can be easily treated with immunotherapy.

Lung Cancer results from an abnormality in the cells of lung.The body maintains a system of checks and balances on cell growth so that cells divide to produce new cells. If this system is interrupted, the uncontrolled division of normal cells into abnormal cell forms a tumor. This tumour represents about 14 % of all the cancer and highest incidence rate is found in age of 65 years and more. Immune oncology therapy might be helpful.

This tumor tends to spread in early stage that’s why it is called as a very life threatening cancer. Lung cancer can spread to any organ of the body such as bone,liver, and adrenal glands. Lung cancer mostly occurs in the lungs of elderly people. In many developing countries, the incidence of lung cancer is beginning to fall following public education about the dangers of cigarette smoking. Across the world, lung cancer is the most common types of cancers in both men and women.

www.gapsos.com

Various sign and symptoms are included in this cancer such as recurrent bronchitis, chest pain, voice chance, persistent cough and hemoptysis. Several risk factors are identified for this tumour such as smoking (most common), tobacco use, randon gas, polluted environment, tuberculosis and radiation exposure.

Small Cell Lung Cancer (SCLC) and Non Small Cell Lung Cancer (NSCLC) are types of lung cancer. NSCLC has subtypes like adenocarinoma, squamous cell carcinoma and large cell carcinoma.

The patients of lung cancer is treated with immunotherapy has shown fewer side effects than other. Immunotherapy and immune combination therapy are advanced treatment for cancer. Although, immunotherapy is based in some immunotherapeutic agents such as monoclonal antibodies, vaccines, checkpoint inhibitor, kinase inhibitors, adoptive T cell therapy and cytokines.

Some monoclonal antibodies such as Bevacizumab and Crizotinib, and some kinase inhibitors such as Erlotinib and Afatinib have received approval by Food and Drug Administration (FDA) for the treatment of lung cancer. Although, many immunotherapeutic agents are running under various phases of clinical trial for FDA approval such as TG4010, CAR CD8 plus PBL, MPDL3280A, Cixutumumab, AMG 102 and erlotinib, Nivolumab, Bavituximab, INGN, Dribble, Patritumab and much more.

Global allied pharmaceuticals (GAP) has team of experts for immunotherapy and immune combination therapy. Our experts providing all essential information about new treatment such as advantages and disadvantages related to patients health, and also plan treatment strategies for patients.

For more information kindly visit us at www.gapsos.com